AstraZeneca PLC (AZN)vsConcentra Group Holdings Parent, Inc. (CON)
AZN
AstraZeneca PLC
$185.95
+1.10%
HEALTHCARE · Cap: $282.69B
CON
Concentra Group Holdings Parent, Inc.
$25.32
+1.61%
HEALTHCARE · Cap: $3.60B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2608% more annual revenue ($60.44B vs $2.23B). AZN leads profitability with a 17.2% profit margin vs 8.0%. CON trades at a lower P/E of 20.2x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
CON
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.1%
Fair Value
$194.57
Current Price
$185.95
$8.62 discount
Intrinsic value data unavailable for CON.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Every $100 of equity generates 42 in profit
Earnings expanding 29.4% YoY
Areas to Watch
Moderate valuation
Distress zone — elevated risk
8.0% margin — thin
Weak financial health signals
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : CON
The strongest argument for CON centers on Return on Equity, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : CON
The primary concerns for CON are Profit Margin, Piotroski F-Score, Altman Z-Score. Debt-to-equity of 5.00 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while CON is a value play — different risk/reward profiles.
CON is growing revenue faster at 13.7% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 59/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Concentra Group Holdings Parent, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Concentra Group Holdings Parent, Inc. (Ticker: CON) is a dynamic diversified holding company focused on acquiring and managing businesses in high-growth sectors, including healthcare, technology, and infrastructure. With a strong commitment to operational excellence and innovation, Concentra employs its experienced leadership team to drive portfolio optimization through strategic investments and hands-on management. This proactive approach enables the company to effectively seize emerging trends and opportunities, positioning it as a compelling investment for institutional investors seeking diversification into high-potential markets.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?